Labcorp has been having an upward trajectory, surpassing
Q2 and Q4 earnings estimates and increasing margins. The stock has also seen a 52-week high at $234.12. In the regulatory space, they have received FDA De Novo Marketing Authorization for PGDx elio™ plasma focus Dx. Notably, they have won a bid for select assets of
Invitae and acquired select assets of BioReference Health's Diagnostics Business. Shareholders in
Labcorp have seen an increase in their investment by 67% over the last five years. Insider activities indicate that some key personnel have sold shares recently. They have also declared a quarterly dividend and updated their updated FY24 Earnings Guidance. Their partnership with
Ultima Genomics has been expanded to advance Whole Genome Sequencing Applications and Oncology Testing Capabilities. Labcorp has further collaborations with Hawthorne Effect to bring clinical trials directly to local communities. Moreover, the company has introduced a new test for Preeclampsia in pregnant Women among other new diagnostic tests.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Sun, 04 Aug 2024 17:10:46 GMT -
Rating 8
- Innovation 5
- Rumor -5
